Medical devices, healthcare technology and the business of care
510(k) clearance · K260796

Tahoe Unicondylar Knee System with TiNbN Overcoat

Shalby Advanced Technologies, Inc. Dba Consensus Orthopedics · Decision date Apr 2, 2026

FDA DECISIONK260796

What did the FDA decide?

FDA records K260796 as a 510(k) premarket notification, with a decision dated Apr 2, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Orthopedic
Decision date
Apr 2, 2026

FDA source record

Regulatory record facts

Identifier
K260796
Regulatory pathway
510(k) premarket notification
Product code
HSX
Decision code
SESE
Decision date
Apr 2, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, Knee, Femorotibial, Non-Constrained, Cemented, Metal/Polymer.

Product code
HSX
FDA device class
2

FDA decision timeline

  1. K260796 received

    Application receipt date recorded by FDA.

  2. K260796 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code HSX

Product / regulatory recordCompanyPathwayDecision dateSource
Maxx Orthopedics, Inc.510(k) clearanceAug 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Shalby Advanced Technologies, Inc. Dba Consensus Orthopedics

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
El Dorado Hills, CA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records